Unknown

Dataset Information

0

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.


ABSTRACT: GLP-1 receptor (GLP-1R) agonists may improve endothelial function (EF) via metabolic improvement and direct vascular action. The current study determined the effect of GLP-1R agonist exenatide on postprandial EF in type 2 diabetes and the mechanisms underlying GLP-1R agonist-mediated vasodilation. Two crossover studies were conducted: 36 participants with type 2 diabetes received subcutaneous exenatide or placebo for 11 days and EF, and glucose and lipid responses to breakfast and lunch were determined; and 32 participants with impaired glucose tolerance (IGT) or diet-controlled type 2 diabetes had EF measured before and after intravenous exenatide, with or without the GLP-1R antagonist exendin-9. Mechanisms of GLP-1R agonist action were studied ex vivo on human subcutaneous adipose tissue arterioles and endothelial cells. Subcutaneous exenatide increased postprandial EF independent of reductions in plasma glucose and triglycerides. Intravenous exenatide increased fasting EF, and exendin-9 abolished this effect. Exenatide elicited eNOS activation and NO production in endothelial cells, and induced dose-dependent vasorelaxation and reduced high-glucose or lipid-induced endothelial dysfunction in arterioles ex vivo. These effects were reduced with AMPK inhibition. In conclusion, exenatide augmented postprandial EF in subjects with diabetes and prevented high-glucose and lipid-induced endothelial dysfunction in human arterioles. These effects were largely direct, via GLP-1R and AMPK activation.

SUBMITTER: Koska J 

PROVIDER: S-EPMC4477348 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.

Koska Juraj J   Sands Michelle M   Burciu Camelia C   D'Souza Karen M KM   Raravikar Kalyani K   Liu James J   Truran Seth S   Franco Daniel A DA   Schwartz Eric A EA   Schwenke Dawn C DC   D'Alessio David D   Migrino Raymond Q RQ   Reaven Peter D PD  

Diabetes 20150226 7


GLP-1 receptor (GLP-1R) agonists may improve endothelial function (EF) via metabolic improvement and direct vascular action. The current study determined the effect of GLP-1R agonist exenatide on postprandial EF in type 2 diabetes and the mechanisms underlying GLP-1R agonist-mediated vasodilation. Two crossover studies were conducted: 36 participants with type 2 diabetes received subcutaneous exenatide or placebo for 11 days and EF, and glucose and lipid responses to breakfast and lunch were det  ...[more]

Similar Datasets

| S-EPMC7262649 | biostudies-literature
| S-EPMC4012905 | biostudies-other
| S-EPMC5391285 | biostudies-literature
| S-EPMC6152343 | biostudies-literature
| S-EPMC4801811 | biostudies-literature
| S-EPMC5990155 | biostudies-literature
| S-EPMC8193264 | biostudies-literature
| S-EPMC7082323 | biostudies-literature
| S-EPMC4931854 | biostudies-literature
| S-EPMC5676476 | biostudies-literature